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Abstract: There is increasing evidence to suggest that extracellular matrix (ECM) 
components play an active role in tumor progression and are an important determinant for 
the growth and progression of solid tumors. Tumor cells interfere with the normal 
programming of ECM biosynthesis and can extensively modify the structure and 
composition of the matrix. In ovarian cancer alterations in the extracellular environment 
are critical for tumor initiation and progression and intra-peritoneal dissemination. ECM 
molecules including versican and hyaluronan (HA) which interacts with the HA receptor, 
CD44, have been shown to play critical roles in ovarian cancer metastasis. This review 
focuses on versican, HA, and CD44 and their potential as therapeutic targets for 
ovarian cancer.  
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1. Introduction  
Ovarian cancer is the most lethal gynecological cancer and ranks as the fifth most common cause of 
cancer-related death in women in the Western world [1,2]. Over 70% of women present with advanced 
disease and despite aggressive treatment, the 5 year survival rate of patients with ovarian carcinoma is 
only 30–50%. This poor prognosis results from late diagnosis and ineffective therapy for advanced 
stage disease. A major challenge for ovarian cancer research remains the identification of tumor 
markers to aid in early diagnosis and the identification of novel therapeutic strategies for advanced 
disease. Significant improvements in ovarian cancer survival will require the development of more 
effective molecularly targeted diagnostics and/or therapeutics. 
2. Ovarian Cancer Metastasis 
Ovarian carcinomas are believed to spread by detaching from the surface of the ovary and attaching 
to and invading the peritoneum which lines the organs of the abdominal cavity. Involvement of the 
peritoneum predicates an adverse situation for the patient which impacts significantly on prognosis. 
This is evidenced by the fact that stage I patients have 5 and 10 year survival rates of over 90%, 
whereas patients with stages III disease have a 5 year survival of only about 30% [3,4]. Ovarian cancer 
cells are anatomically placed to metastasize into the peritoneal cavity. However it is not clear whether 
the anatomical location is solely responsible for intra-peritoneal spread of ovarian carcinomas or 
whether other factors may foster the implantation of cancer cells onto the peritoneal lining. Peritoneal 
cells are known to express and secrete several extracellular matrix (ECM) proteins, adhesion 
molecules and many other factors that provide an important microenvironment to aid the implantation 
of ovarian cancer cells [5–11]. Alterations in the extracellular microenvironment surrounding ovarian 
cancer cells are therefore believed to be critical for tumor initiation, progression and peritoneal tumor 
spread. Indeed, it has been demonstrated that peritoneal cells produce both extracellular matrix 
molecule, hyaluronan (HA) and the HA receptor, CD44 [12–14], and can promote ovarian cancer 
motility by increasing their HA production in co-culture with ovarian cancer cells [14]. 
3. Role of the Extracellular Matrix in Ovarian Cancer Metastasis  
The extracellular matrix (ECM) is a highly organized three-dimensional structure with many 
physiological and pathological roles. The ECM, in addition to maintaining tissue integrity, also 
regulates cell migration, cellular differentiation, and proliferation and also provides a reservoir of 
cytokines and growth factors. Tumor cells interfere with the normal programming of ECM 
biosynthesis and can extensively modify the structure and composition of the matrix [15]. There is 
increasing evidence to suggest that ECM components play an active role in tumor progression and are 
important determinants for the growth and progression of solid tumors [16]. The extensive remodeling 
of the normal ECM in tumors can proceed through the degradation of pre-existing ECM molecules 
and/or by the synthesis of ECM components, which in many cases are not present in the ECM of 
normal tissues. Altered expression of several ECM molecules including versican, hyaluronan (HA) and 
CD44 have been described in ovarian cancer and impact on ovarian cancer outcome [17]. Table 1 
summarizes the studies which have investigated the expression of HA, the HA degrading enzymes Int. J. Mol. Sci. 2011, 12                 
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hyaluronidases, CD44 and versican in ovarian cancer progression and their functional role on ovarian 
cancer cells. 
Table 1. Summary of the studies investigating role of HA, hyaluronidase, CD44 and 
versican effects on epithelial ovarian cancer.  
Molecule Effect  References 
HA  Ovarian cancer cell bind to HA  [6,18] 
  HA is increased at metastatic sites  [19] 
  High HA level predicts poor disease outcome  [20] 
  HA promotes interaction with CD44v3 and HER2 to induce Rac1 and Ras 
signalling and increased ovarian cancer migration and proliferation  
[21] 
  HA and HAS are increased at metastatic sites  [22] 
  HA concentration correlates with high tumor grade  [23] 
  HA promotes motility of ovarian cancer cells  [14] 
  HAS1 levels are associated with reduced survival  [24] 
  HA mediates adhesion of ovarian cancer cells to the peritoneum  [25,26] 
  HA production by mesothelial cells is increased following co-culture with 
ovarian cancer cells  
[14] 
Hyaluronidase  Hyaluronidase activity is increased in metastatic gynecological cancers  [27] 
  Hyaluronidase HYAL1 is reduced in serous ovarian cancer and results in 
HA accumulation 
[28] 
  Hyaluronidase activation is not associated with ovarian cancer 
aggressiveness 
[23] 
  HA and hyaluronidase synthesis by ovarian cancer cells is increased by 
gonadotropins 
[25] 
CD44  CD44 mediates binding peritoneal mesothelium  [13,29,30] 
  Patients with CD44v positive tumors have reduced disease-free survival  [31] 
  CD44 inhibition limits intra-abdominal spreading  [32] 
  CD44-HER2 interactions promote ovarian cancer proliferation  [33] 
  High levels of CD44s is an independent predictor of survival  [34] 
  Loss of CD44v3 expression is an independent factor for poor survival.  [35] 
  CD44 mediates ovarian cancer migration towards ECM  [36] 
  CD44 interaction with c-src kinase promotes HA dependent ovarian 
cancer cell migration 
[37] 
  CD44s expression relates with tumor stage  [38] 
  Decreased CD44s expression correlates with reduced relapse-free survival   [39] 
  Increased expression CD44s predicts improved survival   [40] 
  High CD44 expression is associated with a favorable prognosis  [41] 
  CD44-HA interaction promotes Cdc42 and ERK signaling and ovarian 
cancer progression 
[42] 
  CD44-HA interactions promotes cell migration via HER2 activation and 
beta-catenin nuclear translocation  
[43] 
  Heregulin mediated ErbB2-ERK signaling activates HAS and CD44 
dependent ovarian tumor growth and migration 
[44] 
  Co-expression of CD44 and multiple drug resistance proteins MDR1 and 
MDP2 correlates with ovarian cancer progression 
[45] Int. J. Mol. Sci. 2011, 12                 
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Table 1. Cont. 
Versican  Elevated stromal versican is associated with reduced overall survival   [46] 
  Versican is increased in primary and metastatic cancers  [47] 
  Versican correlates with metastatic signature   [48] 
  Induction of stromal versican expression is associated with tumor 
progression 
[49] 
  High stromal versican associates with poorer outcome  [50] 
  Versican promotes ovarian cancer migration and invasion  [26,50] 
3.1. Role of HA in Ovarian Cancer  
HA is a large polymer which extrudes into the extracellular space and is made up of repeating 
disaccharides of N-acetyl glucosamine and D-glucuronic acid with a varying molecular weight and size 
depending on the tissue in which it is found [51]. HA is synthesized at the surface of cells by one of 
three HA synthases (HAS 1, 2, or 3) and plays a role in various cellular functions including adhesion, 
motility and differentiation [52]. The physiological function of HA varies greatly depending on HA 
size, and the presence or absence of HA binding proteins and cell surface receptors [53,54]  
Many tumors are enriched in HA [53,55]. HA levels can be increased within the tumor cells 
themselves or within the tumoral stroma [20,56]. Increased HA has been shown to be closely 
correlated with the degree of invasiveness and metastatic potential in ovarian cancer tumor 
models [19,22]. Accumulation of high levels of HA have been found to be associated with reduced 
levels of the hyaluronidase HYAL1 [28]. High levels of stromal HA are associated with a poorer 
prognosis in patients with breast cancer, non-small-cell lung cancer, colon cancer, prostate cancer and 
ovarian cancer [20,55–60]. In ovarian cancer patients, high HAS1 levels in ovarian cancer cells but not 
HAS2 or HAS3 are associated with reduced overall survival [24]. This is consistent with other   
reports describing high levels of stromal HA and HAS1 to be independent predictors of overall 
survival [20,24]. Our recent studies have confirmed the presence of high HA levels in the peritumoral 
stroma of serous ovarian carcinomas which correlate with CD44 and versican expression (Figure 1).  
3.2. CD44—A Key Receptor for HA 
The CD44 glycoprotein is an acidic molecule whose charge is largely determined by sialic acid. 
CD44 is a multi-structural cell surface receptor which binds HA with a particularly high 
affinity  [61,62]. It belongs to a family of transmembrane glycoproteins which contain a variable 
extracellular domain, a 23-amino acid transmembrane domain, and a 70-amino acid cytoplasmic 
domain [63]. Up to ten different CD44 isoforms have been documented due to differential splicing of 
the 10 variant exons [64,65]. The most common isoform is the standard CD44 (CD44s), in which 
exon 5 is spliced directly to exon 16 resulting in an approximately 85 kDa glycoprotein.  
3.3. The Role of CD44 and Its Interactions with HA in Cancer 
The binding of HA to CD44 triggers direct cross-signaling between different signaling pathways 
including HER2, c-src kinase and ERK [21,33,37,43,44,66] and it is this function which is thought to 
be involved in increased motility, adhesion, and invasion of cancer cells as well as tumor growth, Int. J. Mol. Sci. 2011, 12                 
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including ovarian cancer [13,32,61,67,68]. High CD44 levels have been associated with unfavorable 
prognosis in a variety of cancers including those of the breast [69], stomach [70], head and neck [71], 
biliary tract [72], and prostate [73]. Ovarian cancers express standard and variant isoforms of 
CD44  [74]. Higher CD44s expression was shown in ovarian cancer compared with benign and 
borderline tumors [75].  
Figure 1. Co-localization of versican, HA and CD44 in ovarian tissues. Normal ovary  
(a, d, g), benign serous cystadenoma (b, e, h) and serous ovarian carcinoma (c, f, i). 
Formalin fixed paraffin sections (5 µm) were immunostained with versican (Vc, 1/500,  
a, b, c) provided by Assoc Prof Richard Le Baron (Division of Life Science, University of 
Texas at San Antonio, San Antonio, TX) previously described [76] following digestion 
with chondroitinase ABC. HA was detected using biotinylated HABP (d, e, f) as described 
previously [77]. CD44 immunohistochemistry (g, h, i) was achieved using mouse anti-CD44 
(1/800 Clone 156-3C11, Neomarkers, Fremont, USA), with citrate buffer microwave 
retrieval. bar = 100 µm. All images are at the same magnification. Strong stromal (St) 
staining for versican, HA and CD44 is present in serous ovarian carcinoma tissue. In 
comparison, lower versican, HA and CD44 stromal staining is present in the stroma of 
normal ovary and benign serous cystadenoma tumor tissues. No versican or HA staining 
was detected in the ovarian surface epithelium (OSE), benign epithelial cells (Ep) or serous 
ovarian carcinoma cells (Ca). 
 Int. J. Mol. Sci. 2011, 12                 
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Several studies have suggested that patients with CD44 positive tumors have a significantly shorter 
disease-free survival than patients with CD44 negative tumors [31,34,38]. In contrast, other studies 
have demonstrated that high CD44s expression is associated with improved ovarian cancer 
outcome [39–41], whilst other studies have found no association between CD44s or CD44 variant 
expression with ovarian cancer metastasis or survival outcome [74,78,79]. 
Differences between the studies could be attributed to technical factors like the use of different 
antibodies and different detection methods. Furthermore, the cohorts of ovarian cancer patients 
examined in the various studies were highly heterogeneous and composed of patients with variable 
tumor types, stages and treatment regimes. Our recent studies have confirmed the presence of high 
CD44 immunostaining particularly in the peritumoral stroma of serous ovarian carcinomas which was 
associated with high HA and versican expression (Figure 1). 
3.4. Versican—An Interacting Partner of HA 
Versican is a large HA binding proteoglycan detected in increased quantities in tumor lesions [80]. 
It is a member of the large aggregating chondroitin sulfate (CS) hyalectins family which includes 
aggrecan, neurocan, and brevican [81]. Versican consists of an N-terminal HA-binding G1 domain, a 
chondroitin sulfate binding region, and a C-terminal, G3 domain [82]. The G1 and G3 domains bind 
specific proteins and have differing domains and motifs which bind to a wide range of molecules 
including fibronectin, and tenascin [83]. Alternative splicing produces five known isoforms of 
versican [84,85]. 
3.5. Versican Is Associated with Poor Outcome 
Elevated levels of versican have been reported in most malignancies, including brain tumors, 
melanomas, osteosarcomas, lymphomas and cancer of the breast, prostate, colon, lung, pancreas, 
endometrium, and ovary [46–48,75,86–98]. Versican expression is also associated with cancer relapse 
and poor patient outcome in breast, prostate and many other cancer types including ovarian cancer [80]. 
Cultured mammary and prostate fibroblasts produced significant amounts of versican  [86,87]. 
Furthermore, it was demonstrated that breast and prostate cancer cells could increase versican 
production by stromal cells [86,87].  
In ovarian cancer, versican has been shown to be present in both cancer cells and the peritumoral 
stroma and increased expression relates with tumor progression and poorer survival outcome [46,49,88]. 
High expression of versican in peritumoral stroma was associated with advanced stage, large residual 
disease, serous histological type, and reduced 5-year survival [46]. Increased expression of versican 
was also identified as a key protein involved in ovarian cancer metastasis [48]. Elevated levels of 
versican have been observed in primary ovarian tumors and secondary metastases when compared with 
normal ovaries [47]. Immunohistochemistry studies in our laboratory have confirmed that versican is 
increased in the stromal compartment of serous ovarian carcinoma compared to the stroma of normal 
ovaries or benign ovarian tumors (Figure 1).  Int. J. Mol. Sci. 2011, 12                 
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3.6. Role of Versican and HA in Promoting Cancer Cell Motility and Invasion 
HA becomes deposited in the tissue spaces immediately surrounding invasive tumors and together 
with other ECM components, forms a protective pericellular coat around the cells [89]. The assembly 
of pericellular matrix rich in HA and versican is a prerequisite for proliferation and migration of 
mesenchymal cells [90] and has recently been shown to promote the motility of prostate cancer 
cells [91]. Our most recent data also shows that motile SKOV-3 ovarian cancer cells expressing CD44 
also form a HA/versican pericellular matrix [26] (Figure 2). Furthermore, we demonstrated that 
versican treatment can induce ovarian cancer cell invasion through an ECM barrier [26]. These 
findings are also supported by a recent study demonstrating that versican-treated ovarian cancer cells 
have increased invasive potential [88]. Our results suggest that formation of a CD44/HA/versican 
macromolecular complex promotes the motility and invasion of ovarian cancer cells. The dependence 
of CD44 for the versican and HA-mediated effects was confirmed by the inhibition of pericellular 
matrix formation as well as versican mediated motility and invasion of ovarian cancer cells following 
treatment with CD44 neutralizing antibody [26]. 
Figure 2. Pericellular matrix formation in motile ovarian cancer SKOV-3 cells. The 
confluent SKOV-3 monolayer was wounded and treated with versican containing media 
(0.5 U/mL) for 4 h. The white asterisks indicate motile SKOV-3 cells with a polar 
pericellular matrix observed over a 70 min time period, using a red blood cell exclusion 
assay. The black asterisks indicate non-motile SKOV-3 cells lacking a pericellular matrix. 
The white arrows indicate the direction of cell movement. Red blood cells diameter = 7 m. 
From Ween et al. [26].  
 
3.7. Involvement of HA and CD44 in the Adhesion of Ovarian Cancer Cells to Peritoneal Cells 
Ovarian cancer cell adhesion to mesothelial cell monolayers is mediated at least in part by the 
interaction between HA and CD44 [6,92]. It has also been suggested that ovarian cancer cell 
interactions with mesothelial cell HA may also mediate tumour metastasis [93]. The addition of   
anti-CD44 antibodies has been reported to significantly decrease adhesion of ovarian cancer cells to 
HA [6]. In vivo studies have suggested that CD44s is required for human ovarian cancer cell adhesion 
to mesothelial cell surface HA [12,29]. Our own in vitro studies have shown that HA increases the 
adhesion of CD44 expressing ovarian cancer cells to peritoneal cells [26].  
Overall the combined data supports a role for versican together with HA and CD44 in a number of 
the key steps needed for ovarian cancer metastasis. Our working model proposes that versican from the Int. J. Mol. Sci. 2011, 12                 
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peritumoral stroma binds HA in the ECM (Figure 3). The formation of a stabilized HA/versican 
pericellular matrix surrounding ovarian cancer cells, protects the ovarian cancer cells against the 
mechanical forces in the peritoneal cavity and enables strong ovarian cancer cell adhesion to CD44 
expressed by peritoneal cells. This provides the basis for subsequent ovarian cancer dissemination 
throughout the abdominal cavity.  
Figure 3. Proposed model of HA, CD44 and versican interactions between ovarian cancer 
and peritoneal cells. The formation of a stabilized HA/versican pericellular matrix 
surrounding ovarian cancer cells increases motility and protects the ovarian cancer cells 
against the mechanical forces in the peritoneal cavity and enable ovarian cancer cells to 
strongly adhere to CD44 expressed on peritoneal cells. This allows subsequent ovarian 
cancer invasion and peritoneal dissemination. From Ween et al. [26].  
 
4. Cancer Therapies Targeting Extracellular Components 
4.1. HA Therapies 
Because of the ability to bind cell surface CD44, which is upregulated in many cancer types, HA 
has been conjugated or co-admininistered with traditional chemotherapy drugs to increase the direct 
targeting of the drug to the cancer cells. More pronounced cytotoxic effects were observed when HA 
was conjugated to paclitaxel on CD44-overexpressing breast cancer cells compared to CD44-deficient 
cells, suggesting that HA-conjugation can be potentially utilized as tumor-targeted therapy [94]. 
Conjugated HA-cisplatin has also been shown to be effective in targeting breast cancer cells in an 
orthotopic mouse model [95].  
In ovarian cancer cells, paclitaxel-HA conjugate interacted with CD44, entered the cells through a 
receptor-mediated mechanism, and exerted a concentration-dependent inhibitory effect on tumor cell Int. J. Mol. Sci. 2011, 12                 
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growth [96]. Furthermore, after intra-peritoneal administration in mice HA bioconjugate distributed 
uniformly within the peritoneal cavity, was well tolerated, and not associated with local toxicity [96]. 
Blood levels of paclitaxel in mice treated with HA-conjugated paclitaxel were also much higher and 
persisted longer than those obtained with the unconjugated paclitaxel [96]. Paclitaxel-HA resulted in a 
2.5-fold increase in therapeutic activity when compared with paclitaxel alone [96] and decreased tumor 
burden in ovarian cancer xenograft mice [97].  
HA has also been investigated as a potential conjugate with other types of cancer therapies besides 
chemotherapy drugs. When polyethylenimine (PEI) DNA particles are conjugated with HA they 
showed more specific targeting of breast cancer cells with high CD44 expression [98]. A siRNA/PEI-HA 
complex exhibited higher CD44 gene silencing efficiency in melanoma cells compared to siRNA/PEI 
complex alone [99] Similarly, liposomes-protamine-HA nanoparticles used for systemic delivery 
of  siRNA into melanoma cells had a broader effective therapeutic dose range than nanoparticles   
without HA [100].  
Methods of eliminating HA in tumors using hyaluronidase enzymes to degrade the HA have also 
been investigated. Pilot clinical studies with a bovine hyaluronidase preparation examined whether this 
enzyme could increase anticancer drug action in combination therapies [101]. However, despite early 
signs of clinical activity, systemic administration of the bovine hyaluronidase elicited allergic reactions 
which, combined with a poor plasma half-life, limited clinical efficacy to local-regional chemotherapy 
in bladder carcinoma [102]. A pegylated variant of human hyaluronidase PH20, PEGPH20 with an 
increased half life has recently been evaluated in prostate cancer xenograft models [103]. In PC3 
prostate tumors, i.v. administration of PEGPH20 depleted tumor HA and significantly inhibited tumor 
growth. PEGPH20 treatment also enhanced both docetaxel and liposomal doxorubicin activity in PC3 
tumors [103]. More recent studies have also demonstrated that mice bearing tumors treated with an 
oncolytic adenovirus expressing PH20 showed more anti tumor efficacy than mice treated with the 
parental virus alone [104]. These results suggest that PH20 may represent a potentially innovative 
treatment approach against tumors which produce high levels of HA which includes the majority of 
ovarian cancers. The company Halozyme has recently commenced a Phase 1 clinical trial which will 
evaluate a range of doses of PEGPH20 in advanced cancer patients [105].  
Thus, HA presents a novel and promising candidate for increasing efficacy and reducing toxicity of 
cancer therapies. HA conjugates also have a potential role in the development of more effective   
intra-peritoneal treatment regimes in ovarian cancer [96]. 
4.2. CD44 Therapies 
CD44 is also promising target against cancer. Methods which have been used to block the action of 
CD44 include, neutralizing antibodies, siRNA, antisense RNA, cDNA vaccination as well as the using 
the naturally occurring CD44-inhibitor silibinin. Silibinin, a natural drug extracted from common 
thistles, which inhibits CD44 promoter activity and expression, is known to have anti-tumor properties 
in breast cancer [106], non small cell lung cancer [107], and colorectal carcinoma [108]. It has also 
been shown to decrease motility and invasion in prostate cancer cells and to decrease adhesion of 
prostate cancer cells to HA and fibronectin [109].  Int. J. Mol. Sci. 2011, 12                 
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CD44 cDNA vaccination has been shown to decrease tumor mass and metastatic potential in 
experimental mammary tumors in mice [110]. In addition, transfection of CD44 antisense RNA into a 
highly metastatic mammary tumor cell line disrupted expression of CD44 in the tumor cells and 
reduced their ability to establish local tumors as well as metastatic colonies in the lung [110]. 
Treatment of gemcitabine resistant pancreatic cancer cells with CD44 siRNA inhibited their 
proliferative activity [111]. Furthermore, in vivo targeting of CD44 by siRNA resulted in anti-tumor 
activity in both colon cancer and leukemia xenografts [112,113]. In hepatocellular carcinomas, CD44 
antisense oligonucleotide significantly down-regulated CD44 expression, induced apoptosis, decreased 
tumorigenesis and invasion, and increased the cancer cell sensitivity to chemotherapy drugs [114]. In 
ovarian cancer cells, in vitro adhesion, invasion, and resistance to apoptosis were inhibited by CD44 
siRNA [115]. Tumor growth and peritoneal dissemination of human ovarian cancer xenografts in nude 
mice were also decreased.  
Another very promising therapeutic approach is the use of anti-CD44 antibodies such as IM7 which 
resulted in a greater than 50% decrease of HA production in glioma cells and enhanced glioma 
apoptosis [116]. Treatment of chondrosarcoma cells with IM7 resulted in a significant decrease in cell 
viability but did not reduce cell viability in normal human chondrocytes [117]. Another antibody 
against CD44, called P245, inhibited growth of breast cancer xenograft in mice [118]. Affify et al. 
showed that anti-CD44s could inhibit breast cancer cell adhesion, motility and invasion, whilst   
anti-CD44v6 inhibited cell motility [119]. Furthermore, Guo et al. showed that treatment with an   
anti-CD44 monoclonal antibodies inhibited the formation of melanoma metastases [120] and decreased 
the invasive ability of breast cancer cells [121]. Treatment of prostate cancer cells with a neutralising 
CD44 antibody decreased cancer cell adhesion to human bone endothelial cells, a primary site for 
prostate cancer cell metastasis [122]. In ovarian cancer, Casey et al. showed that their CD44 
monoclonal antibody did not inhibit ovarian cancer cell invasion but inhibited motility [93], 
Furthermore, Strobel et al. showed a decrease in the number of total peritoneal ovarian cancer 
metastases in mice when treated with a anti-CD44 antibody [32]. However, despite promising in vitro 
studies, clinical trials with CD44 neutralizing antibodies have been terminated due to unacceptable 
levels of toxicity [123]. However, with numerous studies finding that disruption of the HA-CD44 
interaction decreases the proliferative and metastatic behavior of tumor cells, CD44 still remains a 
valid target for anti-cancer therapy. Non toxic alternative therapies need to be developed for future trials. 
4.3. Versican Therapies 
Versican levels in the tumor environment can be reduced by inhibition of its production. This has 
been achieved by treatment with genistein, a tyrosine kinase inhibitor which has been shown to inhibit 
versican synthesis in vascular smooth muscle cells (SMCs) and malignant mesothelioma cell 
lines [124,125]. Versican production could also be blocked by the leukotriene receptor antagonist, 
montelukast, in both bronchial and arterial SMCs [126]. No studies to date have yet investigated 
whether these inhibitors are effective in inhibiting the effects of versican in cancer models.  
More recent studies have demonstrated that drugs used in the treatment of asthma including 
formoterol, a long acting β2-adrenergic
  agonist, and budesonide, a glucocorticoid steroid, could 
decrease protein levels of a number of proteoglycans including versican in airway SMCs and human Int. J. Mol. Sci. 2011, 12                 
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lung fibroblasts [127,128]. Combination treatment with budesonide
 and formoterol was significantly 
superior in reducing versican levels than either drug
 alone [128]. These studies suggest that the 
changes in versican deposition which occur in cancer tissues, as well as the asthmatic airway and 
atherosclerotic lesions, could be inhibited by a number of asthma drugs. This, combined with their safe 
use in humans, makes them potential therapeutic agents against ovarian cancer.  
There is increasing evidence that ADAMTS proteases play an important role in the cleavage of 
versican, and the local accumulation of versican fragments generated by ADAMTS digestion may also 
promote cancer cell motility and invasion. The broad spectrum MMP inhibitor, GM6001 (Galardin) 
which inhibits the activity of MMPs and ADAMTS proteases has been shown to inhibit cancer cell 
invasion and metastasis in several model systems [93,129–131]. One of the more interesting MMP 
inhibitors is present in green tea, which is made from the leaves of Camellia sinensis and contains 
catechin gallate esters. Catechin gallate esters have been shown to selectively inhibit ADAMTS-1,-4, 
and -5 and inhibit aggrecan processing in cartilage tissue [132]. The ability of GM6001 and catechin 
gallate esters to inhibit versican cleavage and versican-induced motility and metastasis of ovarian 
cancer cells has not been investigated yet. Manipulation of the versican catabolic pathways may 
provide novel therapeutic targets against cancer invasion and metastasis.  
The formation of a pericellular matrix rich in HA and versican by vascular SMCs and tumor cells 
can be inhibited following treatment with HA oligomers [26,90,133]. Disruption of the HA-CD44 
interaction with HA oligomers has been shown to markedly inhibit the growth of melanoma 
cells  [134]. Additionally, both link-TSG6 and G1 domain of aggrecan were shown to bind to 
polymeric HA and these interactions could be competed with HA-8 and HA-10 oligomers, 
respectively [135], making it likely that HA oligomers will also block the interaction of versican with 
HA. Treatment with HA-8 oligomers inhibited the formation of pericellular matrix by osteosarcoma 
cells and reduced HA accumulation in local tumors, tumor growth, and the formation of distant lung 
metastases. Furthermore, in osteosarcoma cell lines, both motility and invasiveness were inhibited by 
the use of HA oligomers [136]. Additionally, colorectal carcinoma growth was reduced both in vitro 
and  in vivo after treatment with HA oligomers [137]. Our own recent work has shown that HA 
oligomers can reduce adhesion of ovarian cancer cells to peritoneal cells, and block ovarian cancer 
motility and invasion induced by versican and HA treatment [26]. 
HA oligomers have also been shown to reverse chemotherapy resistance in some cancer cell 
lines [138,139]. Adriamycin resistance of leukemic cells was effectively reversed by HA-4 oligomers 
by increasing the intracellular accumulation of adriamycin [138], whilst in malignant peripheral nerve 
sheath tumors (MPNST), HA oligomers resulted in the disassembly of CD44-transporter complexes 
and induced internalization of CD44 [139]. Furthermore, in vivo systemic administration of HA 
oligomers inhibited the growth of MPNST and ovarian cancer xenografts [139,140]. These findings 
suggest that the potent anti-tumor effects of HA oligomers are due in part to the blocking of the 
formation of HA-rich cell-associated matrices. The use of HA oligomers is a potentially attractive 
reagent to block versican HA interactions as well as local tumor invasion in ovarian cancer but need 
further in vivo investigation. Int. J. Mol. Sci. 2011, 12                 
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5. Conclusions  
Tumor cells interfere with the normal programming of ECM biosynthesis and can extensively 
modify the structure and composition of the matrix. The peritumoral stroma surrounding ovarian 
cancer cells is enriched in HA, versican and CD44 all of which can promote ovarian cancer metastatic 
behavior. These molecules hold promise as therapeutic targets in ovarian cancer and warrant 
further evaluation.  
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